With increased blood sugar levels, diabetes is an autoimmune lifestyle disease affecting about 15 million women in the US. Although the exact cause of diabetes is unknown, changes in lifestyle, genetic factors, and gender could act as some predisposing conditions primarily associated with the disease’s state[i]. The diabetic population continues to increase even though the majority of cases be prevented with simple lifestyle changes[ii].

In women, diabetes is said to be associated with other complications and comorbid conditions. They are at higher risk of developing heart disease, blindness, stroke, kidney damage, and neuropathy as comorbid complications with diabetes. Diabetes can also develop during pregnancy and can lead to health complications for the mother and baby if not controlled or left untreated. The under-diagnosis of diabetes leads to lower survival rates and decreased quality of life leading to depression1,2.

Over the last 80 years, treatment strategies have evolved with vast advancements in technology. There has been a new era in the development of drug therapies and medical devices to monitor your blood sugar levels, keep track of insulin levels, and treat the disease state. With the existing therapies in place, there is an utmost clinical need to diagnose, prevent and mitigate the comorbid conditions associated with diabetes. In the battle against diabetes, the American Diabetes Association has funded over 250 research projects in 123 research institutions to support scientific innovations that lead to healthier lives and a cure for the disease[iii]. Therefore, there is a significant need for the technologies under development to meet the quality, safety, and effectiveness requirements. If you have questions or need guidance, please call us at 248-987-4497 or email us at info@emmainternational.com to strategize your product life cycle.


[i] Womenshealth.gov. 2021. Diabetes | Office on Women’s Health. [online] Available at: <https://www.womenshealth.gov/a-z-topics/diabetes> [Accessed 11 May 2022].

[ii] Fda.gov. 2008. Guidance for Industry Diabetes Mellitus — Evaluating Cardiovascular Risk in New Antidiabetic Therapies to Treat Type 2 Diabetes. [online] Available at: <https://www.fda.gov/media/71297/download> [Accessed 11 May 2022].

[iii] Professional.diabetes.org. 2021. Research & Grants | American Diabetes Association. [online] Available at: <https://professional.diabetes.org/research-grants> [Accessed 11 May 2022].

Vishnu Gotika

Vishnu Gotika

Vishnu is a Regulatory Affairs Specialist at EMMA International. She has experience in R&D product development, regulatory submissions, and compliance activities with pharmaceuticals, medical devices, and IVDs. She holds a Master of Science in Pharmacology and a Master of Science in Regulatory Affairs from Northeastern University.

More Resources

FDA’s Refusal to Accept Process

FDA’s Refusal to Accept Process

Before the submission of a 510(k) premarket notification, the purpose of which is to notify the FDA of the manufacturer’s intent to market a medical device,[i] there is a provision for acceptance review. This review serves as a method to assess whether a submission is administratively complete and includes all necessary information for FDA to determine substantial equivalence under section 513(i) of the Federal Food, Drug, and Cosmetic (FD&C) Act (21 United States Code (U.S.C.) § 360c(i)). To establish substantial equivalence under this provision, FDA must find the same intended use as the predicate device and either have the same technological characteristics as the predicate device or appropriate clinical and scientific data necessary to establish that the device is safe and effective as the predicate device. If the Authority is unable to determine substantial equivalence due to insufficient information, it may request for additional information to make that determination. Therefore, as a part of the acceptance review, the FDA staff follows the acceptance checklist[ii] to ensure that the application is administratively complete. These administrative elements are identified as RTA items and are required to be presented. The purpose of conducting the acceptance review is for the Lead Reviewer to determine whether the 510(k) submission meets the minimum threshold of acceptability and should be accepted for substantive review.[iii]
Empowering Your Workforce through Kaizen

Empowering Your Workforce through Kaizen

Last week, I touched on the idea of involving and empowering all employees in the workplace through the corrective and preventive actions process by fostering taking initiative and a problem-solving (refer to blogpost ‘The Art of Addressing Non-Conformances in Operations’). To expand on this concept a bit further, we’re going to be looking at Kaizen–a continuous improvement strategy in which employees at all levels are also empowered to solve problems towards big gains.
FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

FDA’s draft guidelines on Remote Regulatory Assessments (RRAs)

The pandemic has been a challenging time for all industries including the Food and Drug Administration (FDA). The FDA had to alter the manner in which it conducted its operations. One set of tools adopted by the FDA in response to COVID-19 was the remote regulatory assessment (RRAs).

Ready to learn more about working with us?

Pin It on Pinterest

Share This